Clinical trial NCT00147225: AMG 531 in Patients With Advanced Malignancy Receiving Treatment With Carboplatin
Official title: Phase I/II Study of AMG 531 in Patients With Advanced Malignancy Receiving Treatment With Carboplatin
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
PHASE2
Conditions: Solid Tumors
Advanced Cancer
Keywords: Advanced Cancer
Advanced Malignancy
Solid Tumors
Thrombocytopenia
AMG 531
Romiplostim
Carboplatin
Paraplatin
Platelets
Adriamycin
Doxorubicin
Rubex
Ifosfamide
Ifex
Lead sponsor: M.D. Anderson Cancer Center
Sponsor class: OTHER
Collaborators: name: Amgen
First posted: 2005-09-07
Enrollment: 55
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: PREVENTION

Brief summary: The goal of this clinical research study is to find the highest safe dose of AMG 531 that will decrease the risk and severity of thrombocytopenia (low platelet counts) in patients who have received chemotherapy. Researchers will also look at the safety and effectiveness of AMG 531 (Romiplostim).

Primary Objectives:

1. To determine the clinical safety and tolerability of AMG 531 administered following chemotherapy in patients with advanced malignancy
2. To determine an optimal biologic dose (OBD) of AMG 531 administered in patients receiving chemotherapy known to cause severe thrombocytopenia
3. To evaluate the effects of AMG 531 on the degree and duration of thrombocytopenia and platelet recovery following chemotherapy

Secondary Objective:

1. To evaluate limited pharmacokinetics of AMG 531 administered by S.C. route post-chemotherapy

Detailed description: Platelets are cells that help make the blood clot. A decrease in platelets can cause bleeding, which may prevent or delay a patient from receiving chemotherapy. Researchers want to find out if AMG 531 can lower the risk and severity of this side effect. AMG 531 is a protein that stimulates platelet production.

If you are eligible to take part in this study, you will be assigned to 1 of 6 dosing schedules of study drug. The dose of AMG 531 that you receive will depend on when you are enrolled.

In Cycle 1, all patients will receive chemotherapy by itself. Three (3) weeks later, in Cycle 2, the same dose of chemotherapy will be given followed by AMG 531. AMG 531 will be given on one of 3 schedules. AMG 531 will be given as an injection under the skin on the day after chemotherapy and 2 days later; it will be given 5 days before and the day after chemotherapy; or it will be given 5 and 3 days before chemotherapy and on the day after chemotherapy and 2 days later. The schedule you receive will depend on when you enroll on the study. After 2 cycles of treatment, based on response of the disease and tolerance to the treatment, all participants may be able to receive up to 4 more cycles of chemotherapy followed by AMG 531. All participants will continue on the same schedule you were receiving before. The dose of AMG 531 may be increased at one time point during the study based on the response of the platelet counts.

The number of blood tests drawn (about 3 teaspoons each) will depend on your clinical condition. These samples will be taken at least 2 times a week and as often as once a day during portions of the study. You will also have blood (about 1 teaspoon) collected for the evaluation of anti-AMG 531 antibody status before treatment starts, at the end of Cycles 2 and 4, and at the end of study.

You will be taken off the study if your disease gets worse or intolerable side effects occur. At the end of the study, you will have a medical history and physical exam, including measurement of vital signs. You will also have blood (about 1 teaspoon) drawn for routine tests.

This is an investigational study. AMG 531 is not FDA approved or commercially available. At this time, it is being used for research purposes only. Up to 56 patients will take part in this study. All will be enrolled at University of Texas (UT)MD Anderson.

Eligibility criteria: Inclusion Criteria:

1. Patients with a diagnosis of solid tumors who are at high risk for chemotherapy-induced severe thrombocytopenia related to the following regimens: (a) Carboplatin (AUC=11); (b) AI regimen (adriamycin 75-90mg/m2, Ifosfamide 10gm/m2); (c) High dose Ifosfamide (14gm/m2)
2. Age \>/= 18 years.
3. Adequate hematologic (Absolute neutrophil count (ANC) \>/= 1500/mm\^3, platelet count \>/= 100 x 10\^9/L and Hgb \>/= 8 gm/dL), renal (serum creatinine \</= 2.0 mg/dL), and hepatic functions (total bilirubin \</= 2 times, aspartate aminotransferase (AST or SGOT) or alanine aminotransferase (ALT or SGPT) \</= 3 times the upper limit of the respective normal range).
4. Karnofsky Performance Status \>/= 80
5. Signed informed consent form
6. Patients with childbearing potential (defined as not post-menopausal for 12 months or no previous surgical sterilization) must have a negative pregnancy test and use adequate birth control. \[i.e. oral contraceptives, spermicide with either a condom, diaphragm or cervical cap, use of an intrauterine device (IUD), or abstinence\].

Exclusion Criteria:

1. Patients with rapidly progressive disease (such as patients with rapidly accumulating ascites or pleural effusion).
2. Patients with hematologic malignancies.
3. Pregnant or lactating women.
4. History of central nervous system (CNS) metastasis.
5. Patients with significant cardiac disease (New York Hearth Association (NYHA) Class III or IV), dysrrhythmia, or recent history of MI or ischemia, transient ischemic attack or cerebrovascular accident (CVA), within the previous 6 months of study entry.
6. Patients with a history of thromboembolic events (history of deep venous thrombosis (DVT) or pulmonary embolus).
7. Prior chemotherapy, immunotherapy, or experimental drug (not FDA-approved drug) within 3 weeks. Patients will be eligible if day 1 of chemotherapy was initiated 3 weeks prior to study entry if the patient has recovery of blood counts and from acute toxicity of chemotherapy as described in inclusion criteria # 3.
8. Use of nitrosourea (carmustine (BCNU), lomustine (CCNU) or mitomycin - C within 6 weeks of study entry.
9. Prior surgery or Radiation Therapy (RT) within 2 weeks of study entry.
10. Patients with history of prior whole pelvic radiation will be excluded unless there is no prior history of severe thrombocytopenia (i.e. platelet nadir \<10,000/mm\^3)
11. Patients with history of prior high dose chemotherapy with stem cell transplant or with history of prolonged thrombocytopenia (\>/= 2 weeks).
12. History of any platelet disorders including Idiopathic thrombocytopenic purpura (ITP), Thrombotic thrombocytopenic purpura (TTP) or bleeding disorders.
13. History of \> 4 prior chemotherapy regimens (all platinum regimens will be counted as one regimen).
14. Patients with significant bowel dysfunction secondary to tumor (significant abdominal pain with severe constipation/diarrhea (\>/= Grade 3), significant difficulty maintaining oral nutrition).
15. Patients with pre-existing neuropathy \> Grade 2.

Primary outcomes:
measure: Number of Participants With Adverse Events in Sequential Cohort Dose Escalation Study of AMG 531 Following Chemotherapy
timeFrame: Toxicity assessments with each dose level/cycle (21-28 day cycle) up to 6 cycles
measure: Number of Participants With Venous Thromboembolism (VTE) Related Serious Adverse Events in Sequential Cohort Dose Escalation Study of AMG 531 Following Chemotherapy
timeFrame: Toxicity assessments with each dose level/cycle (21-28 day cycle) up to 6 cycles
Secondary outcomes:
Other outcomes:
Locations:
city: Houston
country: United States
facility: UT MD Anderson Cancer Center
state: Texas
Study officials:
affiliation: UT MD Anderson Cancer Center
name: Saroj Vadhan-Raj, MD
role: PRINCIPAL_INVESTIGATOR
References: